# DESCRIPTION

## BACKGROUND

- describe lysosomal enzymes and their synthesis
- explain lysosomal storage diseases and enzyme replacement therapy
- introduce Glycosylation Independent Lysosomal Targeting (GILT) technology

## SUMMARY OF THE INVENTION

- introduce improved compositions and methods for lysosomal targeting
- describe furin-resistant lysosomal targeting peptides
- describe peptides with reduced binding affinity for insulin receptor
- introduce unexpected discovery of reduced binding affinity
- describe furin-resistant IGF-II mutein
- describe IGF-II mutein with reduced binding affinity for insulin receptor
- describe IGF-II mutein with reduced binding affinity for IGF-I receptor
- describe targeted therapeutic fusion protein with lysosomal enzyme
- describe IGF-II mutein with resistance to furin cleavage
- describe IGF-II mutein with binding to cation-independent M6P receptor
- describe IGF-II mutein with mutations in specific regions
- describe IGF-II mutein with deletion or replacement of amino acids
- describe IGF-II mutein with specific amino acid substitutions
- describe lysosomal enzyme suitable for the invention
- describe targeted therapeutic fusion protein with spacer
- describe nucleic acids encoding IGF-II mutein or fusion protein
- describe pharmaceutical compositions and methods of treatment

## DEFINITIONS

- define amelioration
- define furin-resistant IGF-II mutein
- define furin protease cleavage site
- define furin
- define furin-deficient cells
- define Glycosylation Independent Lysosomal Targeting (GILT)
- define human acid alpha-glucosidase (GAA)
- define improve, increase, or reduce
- define individual, subject, patient
- define lysosomal storage diseases
- define lysosomal enzyme
- define spacer
- define therapeutically effective amount
- define treatment
- describe use of about and approximately
- define specific terms related to Pompe disease
- define specific terms related to Fabry disease
- define specific terms related to Gaucher disease

## DETAILED DESCRIPTION OF THE INVENTION

- introduce GILT technology for lysosomal targeting

### Lysosomal Enzymes

- define lysosomal enzymes
- describe suitable lysosomal enzymes
- specify polypeptide sequence identity
- explain alignment for sequence identity
- introduce Pompe disease as an example

### Pompe Disease

- introduce Pompe disease
- describe symptoms and progression
- explain residual GAA activity correlation
- describe infantile-onset, juvenile-onset, and adult-onset forms
- mention life expectancy and mortality

### Enzyme Replacement Therapy

- introduce enzyme replacement therapy
- describe lysosomal enzyme delivery

### Glycosylation Independent Lysosomal Targeting

- introduce GILT technology
- describe GILT tag and CI-MPR binding

### Furin-Resistant GILT Tag

- introduce furin-resistant GILT tag
- describe furin protease and cleavage site
- show mature human IGF-II peptide sequence
- identify potential furin cleavage sites
- describe mutations to abolish furin cleavage sites
- specify suitable mutations
- describe Lys or Ala substitutions
- mention additional mutations
- specify percentage of residues that can be changed
- describe binding to CI-MPR
- specify dissociation constant
- describe mutations in IGF-II polypeptide
- describe diminished binding affinity for IGF-I receptor
- specify substitutions to reduce affinity
- describe deletion of residues
- describe truncation of C-terminus
- describe binding surfaces for IGF-I and CI-MPR
- describe construction of targeting moiety
- describe minimal regions of IGF-II for binding

### Binding Affinity for the Insulin Receptor

- describe reduced binding affinity for insulin receptor
- specify binding affinity measurement

### Mutagenesis

- introduce mutagenesis
- describe nucleotide changes
- specify conservative and non-conservative mutations
- describe insertions, deletions, and substitutions
- mention scanning amino acid analysis

### Spacer

- describe GILT tag fusion
- describe linker or spacer design

### Cells

- list mammalian cells for expression
- describe HEK 293 cells
- describe CHO cells
- describe monkey kidney cells
- describe HT1080 cells
- describe C10 cells
- describe HeLa cells
- describe BHK cells
- describe 3T3 cells
- describe C127 cells
- describe CV-1 cells
- describe HaK cells
- describe NS/0 cells
- describe L-929 cells
- describe BALB/c mouse myeloma line
- describe human retinoblasts
- describe monkey kidney CV1 line
- describe human embryonic kidney line
- describe baby hamster kidney cells
- describe Chinese hamster ovary cells
- describe mouse sertoli cells
- describe monkey kidney cells
- describe African green monkey kidney cells
- describe human cervical carcinoma cells
- describe canine kidney cells
- describe buffalo rat liver cells
- describe human lung cells
- describe human liver cells
- describe mouse mammary tumor
- describe TR1 cells
- describe MRC 5 cells
- describe FS4 cells
- describe human hepatoma line
- describe insect cells
- describe plant cells
- describe yeast, prokaryote, or fungus cells

## EXAMPLES

### Example 1

- introduce ZC-701 protein
- describe furin cleavage of IGF-II tag
- analyze N-terminal sequencing results
- identify furin cleavage site
- describe SDS-PAGE analysis
- quantify cleaved ZC-701
- discuss implications of furin cleavage
- conclude on ZC-701 heterogeneity

### Example 2

- introduce targeted fusion proteins
- describe mutant versions of ZC-701
- detail construct 1459
- detail construct 1460
- detail construct 1461
- detail construct 1463
- detail construct 1479
- detail construct 1487
- express and analyze mutants
- describe resistance to furin cleavage
- detail construct 1726
- detail construct 1749
- detail construct 1746
- detail construct 1747
- describe deletion mutants
- detail construct 1758
- detail construct 1750
- detail construct 1748
- detail construct 1751
- detail construct 1752
- detail construct 1753
- detail construct 1754
- detail construct 1755
- detail construct 1756
- detail construct 1763

### Example 3

- describe tissue culture
- detail protein purification and concentration
- describe enzyme activity assay
- conclude on GAA expression

### Example 4

- introduce competitive receptor binding assays
- describe IGF2R binding competition assay
- calculate percent bound biotinylated ligand
- determine IC50 values
- compare IC50 values of different proteins
- describe insulin receptor binding assay
- measure competition of biotinylated insulin binding
- compare binding affinity of different proteins
- describe additional insulin receptor binding assay
- analyze binding affinity of ZC-1487 protein

### Example 5

- describe uptake assays
- analyze uptake results of furin resistant GILT-tagged GAA

## EQUIVALENTS

- define equivalents
- interpret articles
- interpret "or" in claims
- include embodiments
- encompass variations
- understand method order

